13th European Headache Federation Congress 2019 - Abstracts

Table 1 (Abstract A22). Efficacy outcomes measures at the end of the first year of the OLEP, Observed (Open-Label Analysis Set)

Outcomes	Values at Week 64 (Week 52 of OLEP)
	Patients on erenumab 140 mg continued on erenumab 140 mg in the OLEP, N=118	Patients on placebo who initiated erenumab 140 mg in the OLEP, N=122	Overall population, N=240
≥50% reduction in MMD	44.3%	50.0%	47.1%
≥75% reduction in MMD	21.4%	25.8%	23.5%
100% reduction in MMD	8.6%	16.7%	12.5%
Change from the DBTP baseline in MMD	−3.8 (3.9)	−3.6 (4.4)	−3.7 (4.1)
Change from the DBTP baseline in HIT-6	−8.5 (7.4)	−9.7 (10.0)	−9.0 (8.7)
Change from the DBTP baseline in MPFID-PI	−5.2 (6.9)	−4.5 (8.4)	−4.8 (7.7)
Change from the DBTP baseline in MPFID-EA	−6.6 (7.7)	−5.1 (9.4)	−5.9 (8.6)

Data are mean (SD) or % of the patients with non-missing value at Week 64; Data for HIT-6 reported at Week 60.
DBTP, double-blind treatment phase; HIT-6, Headache Impact Test; MMD, monthly migraine days; MPFID-EA; Migraine Physical Function Impact Diary-everyday activities MPFID-PI, Migraine Physical Function Impact Diary-physical impairment; N, number of subjects included in the analysis set; OLEP, open-label extension phase; SD, standard deviation

ISSN: 1129-2377